Li Ka Shing Foundation funds histotripsy kidney tumour trials for 30 patients in Hong Kong
Three private hospitals will assess safety and effectiveness of histotripsy, which breaks up tumours with focused sound waves, for kidney cancer; the trials are planned as the first in Asia.
Hong Kong will become the first city in Asia to conduct clinical trials of a non-invasive treatment for kidney tumours, according to scmp.com. The Li Ka Shing Foundation announced on Wednesday that it is funding places for 30 patients across three private hospitals. scmp.com
scmp.comscmp.comOpen source ↗
The trials will be run by CUHK Medical Centre, Gleneagles Hospital Hong Kong and the Hong Kong Sanatorium & Hospital. They will use histotripsy, a technology that applies focused sound waves to break apart tumours without surgical incisions.
The trials will assess the safety and effectiveness of the procedure in kidney cancer. This extends the use of the technology in Hong Kong beyond liver and pancreatic tumours.
